ASCO 2024
ASCO 2024
Advertisement
Ovidio Fernandez Calvo, MDMuscle Invasive Urothelial Carcinoma | June 13, 2024
Dr. Calvo offers insights on an interim analysis of the atezobladderpreserve phase 2 clinical trial in MIBC.
View More
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Alicia Morgans, MD, MPHCRPC | June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas offers long-term outcomes from the JAVELIN Bladder 100 study pertaining to specific patient populations.
Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | June 12, 2024
Dr. Grivas provides an update on relevant clinical trial updates and data readouts pertaining to urothelial carcinoma.
Andrea B. Apolo, MDTesticular, Penile, and Rare Malignancies | June 12, 2024
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Benjamin H. LowentrittASCO 2024 | June 10, 2024
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Vitaly Margulis, MDUpper Tract Urothelial Carcinoma | June 10, 2024
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Tian Zhang, MDProstate Cancer Diagnostics | June 10, 2024
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Tian Zhang, MDAdvanced Renal Cell Carcinoma | June 10, 2024
Dr. Zhang highlights the results of a phase 2 trial for sequential treatment of cabozantinib in advanced RCC.
Samuel Denmeade, MDCRPC | June 6, 2024
Dr. Denmeade highlights his research on blood-based markers of differential efficacy of BAT and enzalutamide in TRANSFORMER.
Michiel van der Heijden, MD, PhDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Soumyajit Roy, MDCRPC | June 6, 2024
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Antonio Cigliola, MDMuscle Invasive Urothelial Carcinoma | June 6, 2024
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | June 6, 2024
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Roger Li, MDNon-Muscle Invasive Urothelial Carcinoma | June 6, 2024
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Manmeet Ahluwalia, MD, MBA, FASCOAdvanced Renal Cell Carcinoma | June 10, 2024
The combination of SRS with IO significantly increases the OS in RCCBM compared with IO, WBRT, or WBRT plus IO.
Zachary BessetteCRPC | June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Advertisement
Advertisement
Advertisement